Significant Acquisition by ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) mad
AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) ( STTK), a biotechnology company pioneering the development of nov
AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) ( STTK), a biotechnology company pioneering the development of nov
On December 4, 2024, Redmile Group, LLC (Trades, Portfolio) made a strategic decision to reduce its position in Shattuck Labs Inc (NASDAQ: STTK). The firm sold
AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) ( STTK), a biotechnology company pioneering the development of nov
Overview of FMR LLC (Trades, Portfolio)'s Recent Transaction On November 6, 2024, FMR LLC (Trades, Portfolio) executed a significant reduction in its holdings o
Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Florida-based Ontrak, Inc. (OTRK) is up over 65 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic...
The IDH inhibitors market is expected to grow significantly in the coming years. This is due to the rising occurrence of IDH-mutated cancers, such as acute...
China-based CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company is up over 43 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.
June 17, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform releases the first of a two-part series looking at developments for the...
Sep 08, 2022 / 06:40PM GMTYigal Dov Nochomovitz - Citigroup Inc., Research Division - Director Yigal Nochomovitz, I'm one of the biotech analysts here at Citi.
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.